Tithon Animal Sciences, Inc., was formed with the vision of providing technology and products to companion animal and horse owners and to  the veterinarian medical community at large with the goal of relieving companion animals and horses suffering from degenerative medical conditions.

Tithon’s advanced technologies, products, methods, processes and procedures are based on research undertaken by pioneers in the cell therapy research field, assisted by university researchers and practicing veterinarian medical specialists. We are committed to developing revolutionary treatment options for those companion animals and horses suffering from degenerative medical conditions, options that are both safe and effective.

Tithon Human Sciences, Inc.,, was formed with the vision of providing relief from human suffering resulting from degenerative medical conditions, including aging, through proprietary technologies, products, methods, processes and procedures, developed by pioneers in the field of cellular and other biotechnologies.

To this end, we are opening Tithon Regenerative Centers in strategic locations around the world, each dedicated to the development and support of carefully selected and qualified Licensed Clinic Locations, each offering Tithon’s advanced technologies, products, methods, processes and procedures in their practice of medicine.

Tithon Life Sciences, Ltd., was formed with the vision of improving human and animal fertility. We have recently developed technologies, products, processes, methods and procedures specifically designed to increase female fertility based on proprietary medical discoveries useful in diagnosing and treating maternal immune response to paternal antigens; and a method for harvesting and processing a distinct population of peripheral blood derived pluripotent stem cells (PBD-PSC) shown useful in improving ovarian function and the thickness and receptivity of endometrium tissue.

Tithon Immunosciences, Inc. was formed with the vision of providing relief from suffering resulting from autoimmune disease, by providing a line of proprietary diagnostic tests and drugs, based upon a proprietary drug-development platform that the Company has labeled “antigen-specific immunotherapy.” Early testing has shown this Antigen-Specific Immunotherapy Technology effective in both diagnosing certain autoimmune conditions and in addressing symptoms related to a number of autoimmune disorders through the desensitization of the body’s immune response to attack of self-tissues by the body’s own antibodies.